|Day's Range||0.023 - 0.025|
|52 Week Range||0.023 - 0.042|
|PE Ratio (TTM)||-6.25|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Prima Biomed Ltd. (PBMD) announced that a new clinical study, INSIGHT, on its lead candidate IMP321 has received regulatory approval for initiation
Prima is running trials to treat breast cancer and skin cancer using combinations of its drug IMP321.
Prima (PBMD) dosed the first patient in the enlarged randomized phase of the phase IIb study -- AIPAC -- on IMP321 for the treatment of metastatic breast cancer.